Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

11.3K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

5.7K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<b>Taxonomy of the leafhopper genus <i>Limentinus</i> (Hemiptera: Cicadellidae: Coelidiinae) with description of three new species from Madagascar</b>.

Zootaxa·2026
Same author

From cross cancer transcriptomics to therapeutics: WGX-50 target hub genes in breast cancer and non-small cell lung carcinoma.

Computational biology and chemistry·2026
Same author

Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study.

American journal of hematology·2026
Same author

LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma.

Cell death & disease·2026
Same author

Effects of magnesium potassium sulfate on Tibetan sheep quality and its volatile and non-volatile metabolic substances.

Frontiers in nutrition·2026
Same author

Mutation Profiling, Efficacy Monitoring, and Prognosis Evaluation Using Circulating Tumor DNA in Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Observational Study.

American journal of hematology·2026

Related Experiment Video

Updated: May 20, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

9.7K

MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B-Cell Lymphoma.

Yan Li1,2, Cunzhen Shi1, Jiazhuo Wu1

  • 1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Hematological Oncology
|May 19, 2025
PubMed
Summary
This summary is machine-generated.

MerTK is highly expressed in diffuse large B-cell lymphoma (DLBCL). Inhibiting MerTK suppresses DLBCL cell growth and progression, offering a potential new precision therapy target for this aggressive cancer.

Keywords:
ANXA1MerTKautophagydiffuse large B‐cell lymphomatargeted therapy

More Related Videos

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.0K
Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.7K

Related Experiment Videos

Last Updated: May 20, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

9.7K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.0K
Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) lacks effective rescue treatments.
  • Identifying novel therapeutic targets is crucial for improving DLBCL patient outcomes.

Purpose of the Study:

  • To investigate the role of MerTK (a proto-oncogene) as a therapeutic target in DLBCL.
  • To evaluate the efficacy of MerTK inhibition in preclinical DLBCL models.

Main Methods:

  • Immunohistochemistry and western blotting to assess MerTK expression in DLBCL.
  • MerTK knockdown using shRNA in DLBCL cell lines and xenograft models.
  • Treatment with UNC2025, a MerTK small molecule inhibitor.
  • Transcriptome sequencing and KEGG pathway analysis.

Main Results:

  • Aberrant high expression of MerTK was observed in DLBCL samples and cell lines.
  • MerTK inhibition (knockdown or UNC2025) reduced DLBCL cell proliferation, induced apoptosis, and caused G2/M arrest.
  • MerTK inhibition altered gene expression, significantly enriching the autophagy pathway and upregulating ANXA1.
  • MerTK inhibition suppressed autophagy flow by increasing ANXA1 expression.
  • MerTK inhibition decreased tumor growth in vivo in DLBCL xenograft models.

Conclusions:

  • MerTK is ectopically expressed in DLBCL and drives tumor growth.
  • Targeted inhibition of MerTK demonstrates significant anti-tumor activity in vitro and in vivo.
  • MerTK represents a promising target for precision therapy in DLBCL.